Abstracts tagged "Antibodies"

Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Savino Sciascia¹, Mª Jose Cuadrado², Giovanni Sanna³, Veronica Murru⁴, Dario Roccatello¹, Oier Ateka⁵, Munther A. Khamashta⁶ and Maria Laura Bertolaccini⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Lupus Research Unit, The Rayne Institute, London, United Kingdom, ³Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Unit, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…
Abstract Number: 286 • 2012 ACR/ARHP Annual Meeting
The Association of N-Methyl-D-Aspartate Receptor Antibodies and Neurocognitive Dysfunction in Pediatric Lupus Patients and in the Offspring of Adult Patients with Lupus
Natasha M. Ruth¹, Mary C. Kral², Stephanie Slan³, Tamara K. Nowling⁴, Murray H. Passo¹ and Gary S. Gilkeson³, ¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²Genetics and Developmental Pediatrics, MUSC, Charleston, SC, ³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC
Background/Purpose: Approximately 1/5 of all systemic lupus erythematosus (SLE) starts in childhood and central nervous system (CNS) dysfunction is more common in childhood-onset SLE. CNS…
Abstract Number: 2618 • 2012 ACR/ARHP Annual Meeting
Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy
Eduardo F. Borba¹, Sandra G. Pasoto¹, Ana L. Calich¹, Ricardo Fuller¹, Vilma S.T. Viana¹, Margareth Vendramini¹, Joao Miraglia², Maria A. Ishida³ and Eloisa Bonfa⁴, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Instituto Butantan, Fundação Butantan, São Paulo, Brazil, ³Instituto Adolfo Lutz, São Paulo, Brazil, ⁴Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: To determine the influence of disease activity without the effect of drugs in pandemic 2009 influenza A (H1N1) vaccine immune response in untreated systemic…
Abstract Number: 216 • 2012 ACR/ARHP Annual Meeting
Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis
Yuji Hosono¹, Ran Nakashima¹, Yoshitaka Imura², Naoichiro Yukawa³, Hajime Yoshifuji¹, Motomu Hashimoto⁴, Koichiro Ohmura⁵, Takao Fujii⁶ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic connective tissue disorders, which are often associated with internal malignancy. Several studies have reported the association between…
Abstract Number: 2659 • 2012 ACR/ARHP Annual Meeting
An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis
Jon T. Giles¹, Sonye Danoff², Jeremy Sokolove³, Robert Winchester⁴, Dimitrios A. Pappas⁵, Catriona Cramb⁶, Geoffrey Connors⁷, Stanley S. Siegelman⁸, William H. Robinson⁹ and Joan M. Bathon⁵, ¹Medicine, Columbia University, New York, NY, ²Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ³Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Dept of Medicine & Pathology, Columbia University, New York, NY, ⁵Columbia University, New York, NY, ⁶VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ⁷Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, CT, ⁸Department of Radiology, Johns Hopkins University, Baltimore, MD, ⁹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Interstitial lung disease (ILD) is an outcome with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed in these lung tissues;…
Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting
Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Clifton O. Bingham III¹, Warren C. Rizzo², Micki Klearman³, Azra Hassanali⁴, Ruchi Upmanyu⁵ and Alan J. Kivitz⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Advanced Arthritis Care & Research, Scottsdale, AZ, ³Genentech Inc, South San Francisco, CA, ⁴Genentech Inc, San Francisco, CA, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Mathieu Verdet¹, Clément Guillou², Marie-Laure Potier², Martine Hiron², Fabienne Jouen³, Olivier Boyer⁴, Thierry Lequerré⁵ and Olivier Vittecoq⁶, ¹Rheumatology, Rouen University Hospital, Bois Guillaume, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Immunology, Rouen University Hospital, Rouen Cedex, France, ⁴Immunology, INSERM U905, University of Rouen, Rouen, France, ⁵Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
Abstract Number: 665 • 2012 ACR/ARHP Annual Meeting
Cytokines and Their Relation to Autoantibodies Before Disease Onset in Systemic Lupus Erythematosus
Catharina Eriksson¹ and Solbritt Rantapää Dahlqvist², ¹Department of Clinical Immunology/clinical microbiology, Umeå, Sweden, ²Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden
Background/Purpose: Cytokines and autoantibodies are involved in the pathogenesis of systemic lupus erythematosus (SLE). The presence of autoantibodies preceding disease onset by years has been…
Abstract Number: 683 • 2012 ACR/ARHP Annual Meeting
Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme 2 (ACE2) in Patients with Systemic Lupus Erythematosus
Yuko Takahashi¹, Shiori Haga², Yukihito Ishizaka² and Akio Mimori³, ¹Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, ³Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan
Background/Purpose: We previously reported that inhibitory autoantibodies to angiotensin converting enzyme 2 (ACE2) predisposed individuals to connective tissue diseases (i.e., scleroderma or systemic lupus erythematosus…
Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting
Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial
Ladislav ŠEnolt¹, Marie Göthberg², Xavier Valencia³ and Eva Dokoupilova⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Biostatistics, Novo Nordisk, A/S, Soeborg, Denmark, ³Clinical Medical and Regulatory Affairs, Novo Nordisk, Inc., Princeton, NJ, ⁴Medical Plus s.r.o, Uherske Hradiste, Czech Republic
Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…
Abstract Number: 835 • 2012 ACR/ARHP Annual Meeting
Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Adrienne O'Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, Dallas, TX
Background/Purpose: B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…
Abstract Number: 948 • 2012 ACR/ARHP Annual Meeting
Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing
Ryo Rokutanda¹, Mitsumasa Kishimoto¹, Yasuharu Tokuda², Ken-ichi Yamaguchi¹, Hisanori Shimizu¹, Yasuhiro Suyama¹, Yuri Ohara¹, Yoichiro Haji¹, Chisun Min¹, Akira Takeda¹, Yukio Matsui³ and Masato Okada¹, ¹Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Antinuclear antibody (ANA) is widely used as a screening test for connective tissue diseases (CTDs). The sensitivity of this test is high in 3…
Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting
IL-6 and IL-21 in Rheumatoid Arthritis
Gustavo Carbone¹, Augusta Wilson¹, Sean Diehl², Janice Bunn³, Sheldon Cooper⁴ and Mercedes Rincon⁵, ¹Rheum & Clinical Imm Unit, University of Vermont College of Medicine, Burlington, VT, ²Immunobiology, University of Vermont College of Medicine, ³Mathematics and Statistics, University of Vermont, Burlington, VT, ⁴Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT, ⁵Immunobiology, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 1491 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells
Jeannine Guenther¹, Angela Kill², Mike O. Becker³ and Gabriela Riemekasten⁴, ¹Rheumatology/Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Berlin, Germany, ²Rheumatology and clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany
Background/Purpose: Autoimmunity, vasculopathy and fibrosis are features of systemic sclerosis (SSc). The functional link between these three pathophysiological components is still missing. Research suggests an…